Global Inhalers and Nebulizers 麻豆原创 Growth 2025-2031

Publication ID:

LPI04252820

Publication Date:

April 25, 2025

Pages:

135

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

The global Inhalers and Nebulizers market size is predicted to grow from US$ 15350 million in 2025 to US$ 19450 million in 2031; it is expected to grow at a CAGR of 4.0% from 2025 to 2031.
Devices that are used to deliver medicine in a fine mist directly into the lungs. They are used to treat asthma and other lung diseases, such as chronic obstructive lung disease (COPD). These devices cause fewer side effects than medicine taken by mouth or injection.
Inhalers and nebulizers are two different devices used to deliver quick-relief medicines (also called rescue or fast-acting medicines) or long-term control medicines (also called controller or maintenance medicines) directly into the lungs.
Inhalers is drug-device combination products, in our report, we study the inhalers with drugs. For nebulizers we only study the devices.
The increasing prevalence of respiratory disorders, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis, is a major driver for the inhalers and nebulizers market. Rising air pollution levels and lifestyle changes have contributed to the growing incidence of these conditions. Additionally, advancements in inhaler and nebulizer technology, including portable and smart devices, enhance medication delivery efficiency and patient adherence. The shift toward home-based care and the increasing adoption of self-administered treatments also support market growth, providing convenience and reducing the burden on healthcare facilities.
Despite their widespread adoption, the inhalers and nebulizers market faces challenges such as high costs of advanced devices and limited access in low-income regions. Incorrect usage of inhalers due to a lack of patient education often leads to suboptimal treatment outcomes, reducing their effectiveness. Furthermore, environmental concerns associated with the use of hydrofluoroalkane (HFA) propellants in inhalers have prompted regulatory scrutiny, leading to the need for eco-friendly alternatives. These factors, combined with stiff competition among manufacturers, pose hurdles to the market's growth.
Global key manufacturers of Inhalers and Nebulizers include GSK, AstraZeneca, Chiesi, Boehringer Ingelheim, Teva, etc. Global top five manufacturers hold a share about 75%. North America is the largest market of Inhalers and Nebulizers, holds a share over 35%. In terms of product, the Inhalers holds a share of over 90%. And in terms of application, the largest application field is Asthma, with a share of over 45%.
The 鈥淚nhalers and Nebulizers Industry Forecast鈥� looks at past sales and reviews total world Inhalers and Nebulizers sales in 2024, providing a comprehensive analysis by region and market sector of projected Inhalers and Nebulizers sales for 2025 through 2031. With Inhalers and Nebulizers sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Inhalers and Nebulizers industry.
This Insight Report provides a comprehensive analysis of the global Inhalers and Nebulizers landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Inhalers and Nebulizers portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Inhalers and Nebulizers market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Inhalers and Nebulizers and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Inhalers and Nebulizers.
This report presents a comprehensive overview, market shares, and growth opportunities of Inhalers and Nebulizers market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Inhalers
Nebulizer
Segmentation by Application:
Asthma
COPD
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
GSK
AstraZeneca
Chiesi
Boehringer Ingelheim
Novartis
Teva
Organon
PARI GmbH
Omron
Philips
Drive DeVilbiss Healthcare
Yuwell
Leyi
Folee
Beurer
YHRT MEDICAL
YUEHUA
CONTEC
Key Questions Addressed in this Report
What is the 10-year outlook for the global Inhalers and Nebulizers market?
What factors are driving Inhalers and Nebulizers market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Inhalers and Nebulizers market opportunities vary by end market size?
How does Inhalers and Nebulizers break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Inhalers and Nebulizers Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Inhalers and Nebulizers by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Inhalers and Nebulizers by Country/Region, 2020, 2024 & 2031
2.2 Inhalers and Nebulizers Segment by Type
2.2.1 Inhalers
2.2.2 Nebulizer
2.3 Inhalers and Nebulizers Sales by Type
2.3.1 Global Inhalers and Nebulizers Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Inhalers and Nebulizers Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Inhalers and Nebulizers Sale Price by Type (2020-2025)
2.4 Inhalers and Nebulizers Segment by Application
2.4.1 Asthma
2.4.2 COPD
2.4.3 Others
2.5 Inhalers and Nebulizers Sales by Application
2.5.1 Global Inhalers and Nebulizers Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Inhalers and Nebulizers Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Inhalers and Nebulizers Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Inhalers and Nebulizers Breakdown Data by Company
3.1.1 Global Inhalers and Nebulizers Annual Sales by Company (2020-2025)
3.1.2 Global Inhalers and Nebulizers Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Inhalers and Nebulizers Annual Revenue by Company (2020-2025)
3.2.1 Global Inhalers and Nebulizers Revenue by Company (2020-2025)
3.2.2 Global Inhalers and Nebulizers Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Inhalers and Nebulizers Sale Price by Company
3.4 Key Manufacturers Inhalers and Nebulizers Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Inhalers and Nebulizers Product Location Distribution
3.4.2 Players Inhalers and Nebulizers Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Inhalers and Nebulizers by Geographic Region
4.1 World Historic Inhalers and Nebulizers 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Inhalers and Nebulizers Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Inhalers and Nebulizers Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Inhalers and Nebulizers 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Inhalers and Nebulizers Annual Sales by Country/Region (2020-2025)
4.2.2 Global Inhalers and Nebulizers Annual Revenue by Country/Region (2020-2025)
4.3 Americas Inhalers and Nebulizers Sales Growth
4.4 APAC Inhalers and Nebulizers Sales Growth
4.5 Europe Inhalers and Nebulizers Sales Growth
4.6 Middle East & Africa Inhalers and Nebulizers Sales Growth
5 Americas
5.1 Americas Inhalers and Nebulizers Sales by Country
5.1.1 Americas Inhalers and Nebulizers Sales by Country (2020-2025)
5.1.2 Americas Inhalers and Nebulizers Revenue by Country (2020-2025)
5.2 Americas Inhalers and Nebulizers Sales by Type (2020-2025)
5.3 Americas Inhalers and Nebulizers Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Inhalers and Nebulizers Sales by Region
6.1.1 APAC Inhalers and Nebulizers Sales by Region (2020-2025)
6.1.2 APAC Inhalers and Nebulizers Revenue by Region (2020-2025)
6.2 APAC Inhalers and Nebulizers Sales by Type (2020-2025)
6.3 APAC Inhalers and Nebulizers Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Inhalers and Nebulizers by Country
7.1.1 Europe Inhalers and Nebulizers Sales by Country (2020-2025)
7.1.2 Europe Inhalers and Nebulizers Revenue by Country (2020-2025)
7.2 Europe Inhalers and Nebulizers Sales by Type (2020-2025)
7.3 Europe Inhalers and Nebulizers Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Inhalers and Nebulizers by Country
8.1.1 Middle East & Africa Inhalers and Nebulizers Sales by Country (2020-2025)
8.1.2 Middle East & Africa Inhalers and Nebulizers Revenue by Country (2020-2025)
8.2 Middle East & Africa Inhalers and Nebulizers Sales by Type (2020-2025)
8.3 Middle East & Africa Inhalers and Nebulizers Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Inhalers and Nebulizers
10.3 Manufacturing Process Analysis of Inhalers and Nebulizers
10.4 Industry Chain Structure of Inhalers and Nebulizers
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Inhalers and Nebulizers Distributors
11.3 Inhalers and Nebulizers Customer
12 World Forecast Review for Inhalers and Nebulizers by Geographic Region
12.1 Global Inhalers and Nebulizers 麻豆原创 Size Forecast by Region
12.1.1 Global Inhalers and Nebulizers Forecast by Region (2026-2031)
12.1.2 Global Inhalers and Nebulizers Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Inhalers and Nebulizers Forecast by Type (2026-2031)
12.7 Global Inhalers and Nebulizers Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Inhalers and Nebulizers Product Portfolios and Specifications
13.1.3 GSK Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Inhalers and Nebulizers Product Portfolios and Specifications
13.2.3 AstraZeneca Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Chiesi
13.3.1 Chiesi Company Information
13.3.2 Chiesi Inhalers and Nebulizers Product Portfolios and Specifications
13.3.3 Chiesi Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Chiesi Main Business Overview
13.3.5 Chiesi Latest Developments
13.4 Boehringer Ingelheim
13.4.1 Boehringer Ingelheim Company Information
13.4.2 Boehringer Ingelheim Inhalers and Nebulizers Product Portfolios and Specifications
13.4.3 Boehringer Ingelheim Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Boehringer Ingelheim Main Business Overview
13.4.5 Boehringer Ingelheim Latest Developments
13.5 Novartis
13.5.1 Novartis Company Information
13.5.2 Novartis Inhalers and Nebulizers Product Portfolios and Specifications
13.5.3 Novartis Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Novartis Main Business Overview
13.5.5 Novartis Latest Developments
13.6 Teva
13.6.1 Teva Company Information
13.6.2 Teva Inhalers and Nebulizers Product Portfolios and Specifications
13.6.3 Teva Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Teva Main Business Overview
13.6.5 Teva Latest Developments
13.7 Organon
13.7.1 Organon Company Information
13.7.2 Organon Inhalers and Nebulizers Product Portfolios and Specifications
13.7.3 Organon Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Organon Main Business Overview
13.7.5 Organon Latest Developments
13.8 PARI GmbH
13.8.1 PARI GmbH Company Information
13.8.2 PARI GmbH Inhalers and Nebulizers Product Portfolios and Specifications
13.8.3 PARI GmbH Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 PARI GmbH Main Business Overview
13.8.5 PARI GmbH Latest Developments
13.9 Omron
13.9.1 Omron Company Information
13.9.2 Omron Inhalers and Nebulizers Product Portfolios and Specifications
13.9.3 Omron Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Omron Main Business Overview
13.9.5 Omron Latest Developments
13.10 Philips
13.10.1 Philips Company Information
13.10.2 Philips Inhalers and Nebulizers Product Portfolios and Specifications
13.10.3 Philips Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Philips Main Business Overview
13.10.5 Philips Latest Developments
13.11 Drive DeVilbiss Healthcare
13.11.1 Drive DeVilbiss Healthcare Company Information
13.11.2 Drive DeVilbiss Healthcare Inhalers and Nebulizers Product Portfolios and Specifications
13.11.3 Drive DeVilbiss Healthcare Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Drive DeVilbiss Healthcare Main Business Overview
13.11.5 Drive DeVilbiss Healthcare Latest Developments
13.12 Yuwell
13.12.1 Yuwell Company Information
13.12.2 Yuwell Inhalers and Nebulizers Product Portfolios and Specifications
13.12.3 Yuwell Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Yuwell Main Business Overview
13.12.5 Yuwell Latest Developments
13.13 Leyi
13.13.1 Leyi Company Information
13.13.2 Leyi Inhalers and Nebulizers Product Portfolios and Specifications
13.13.3 Leyi Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Leyi Main Business Overview
13.13.5 Leyi Latest Developments
13.14 Folee
13.14.1 Folee Company Information
13.14.2 Folee Inhalers and Nebulizers Product Portfolios and Specifications
13.14.3 Folee Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Folee Main Business Overview
13.14.5 Folee Latest Developments
13.15 Beurer
13.15.1 Beurer Company Information
13.15.2 Beurer Inhalers and Nebulizers Product Portfolios and Specifications
13.15.3 Beurer Inhalers and Nebulizers Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Beurer Main Business Overview
13.15.5 Beurer Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.